embecta Completes Acquisition of Owen Mumford Holdings Limited
Rhea-AI Summary
embecta (Nasdaq: EMBC) has completed its acquisition of Owen Mumford Holdings, a UK-based medical device and drug delivery innovator. The deal includes a £100 million upfront cash payment and up to £50 million in performance-based payments tied to Aidaptus® auto-injector net sales.
The transaction is intended to accelerate embecta’s shift into a broad medical supplies and drug delivery platforms business, expanding its chronic care product portfolio, intellectual property, manufacturing capabilities, and global commercial reach across obesity, diabetes, autoimmune diseases and anaphylaxis markets.
Positive
- Acquisition of Owen Mumford completed with £100 million upfront cash payment
- Up to £50 million additional performance-based payments linked to Aidaptus® net sales
- Expansion into broader drug delivery platforms for pharmaceutical partners
- Strengthened chronic care product portfolio across multiple therapeutic areas
- Addition of Aidaptus® next-generation auto-injector and related intellectual property
- Combined design, molding, assembly and large-scale manufacturing for efficiencies and reach
Negative
- None.
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 19 | Acquisition agreement | Positive | +2.9% | Announced definitive deal to acquire Owen Mumford for up to £150M. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited acquisition history; the prior Owen Mumford agreement on Mar 19, 2026 saw a modest positive move of 2.93% after the announcement.
Recent news shows embecta balancing strategic moves with financial pressure. On Mar 19, 2026, it announced the Owen Mumford agreement, which added drug-delivery platforms and a £69.4M revenue base and saw a 2.93% gain. Subsequent filings on May 5, 2026 reported revenue declines, a net loss, guidance cuts, and a sharp dividend reduction. Completion of the Owen Mumford acquisition now follows through on that previously disclosed deal, reinforcing the shift toward broader drug-delivery and chronic care platforms.
Key Terms
auto-injector medical
drug delivery medical
intellectual property technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global leader in diabetes care technology, today announced that it has completed its previously announced transaction to acquire Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug delivery technologies.
On March 19, 2026, the two companies announced a definitive agreement for embecta to acquire Owen Mumford for an upfront cash payment of
The transaction accelerates embecta’s strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients in the obesity, diabetes, autoimmune diseases and anaphylaxis markets. It provides embecta a differentiated drug-delivery platform designed to support pharmaceutical partners across multiple therapeutic areas and a strong underlying intellectual property portfolio, including the next-generation Aidaptus® auto-injector platform. It further adds a product portfolio of chronic care devices and leverages core manufacturing strengths in high volume medical products by combining Owen Mumford’s device design, molding and assembly capabilities in drug-delivery systems with embecta’s global commercial and distribution infrastructure, and large-scale manufacturing expertise, creating opportunities for expanding geographic reach and operational efficiencies.
About embecta
embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,500 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
About Owen Mumford
Founded in 1952 and headquartered in Oxfordshire, United Kingdom, Owen Mumford is a medical technology company with more than 70 years of innovation in healthcare device development. The company has built a strong reputation as a trusted partner to pharmaceutical and biotechnology companies, developing drug delivery technologies that support the administration of complex therapies, including its next-generation Aidaptus® auto-injector platform designed to enable future pharmaceutical partnerships. In addition to its drug delivery capabilities, Owen Mumford also offers a portfolio of medical devices used in chronic care and point-of-care applications, including self-injection, diagnostics and other patient-focused healthcare solutions distributed in markets around the world.
SAFE HARBOR STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains express or implied “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding strategic direction and priorities and expectations regarding our acquisition of Owen Mumford. These forward-looking statements are subject to various known and unknown risks, uncertainties and other factors, and you should not rely upon them except as statements of our present intentions and of our present expectations, which may or may not occur. When we use words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “pursue,” “will,” “goal” or similar expressions, we are making forward-looking statements. Although we believe that our forward-looking statements are based on reasonable assumptions, our expected results may not be achieved, and actual results may differ materially from our expectations. In addition, important factors that could cause actual results to differ from expectations include, among others, the risks described in our periodic reports filed with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, as further updated by our Quarterly Reports on Form 10-Q we have filed or will file hereafter. Except as required by law, we undertake no obligation to update any forward-looking statements appearing in this release.
| Contacts | |
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| Contact Media Relations | Contact IR |
